Last updated: February 24, 2026
What is the scope of patent ES2606041?
Patent ES2606041 covers the preparation method and composition of a novel anticancer compound. It primarily claims the synthesis process, the chemical structure of the active ingredient, and specific formulations for therapeutic use. The patent aims to protect both the compound itself and key variants used in combination therapies.
Key features:
- Compound: A specific amidopyridine derivative designed for enhanced anticancer activity.
- Synthesis: A multistep chemical process involving selective substitution reactions.
- Formulation: Pharmaceutical compositions incorporating the compound, with detailed claims on dosage forms like tablets, capsules, and injectables.
- Therapeutic use: Treatment of specific cancers, including non-small cell lung carcinoma and breast carcinoma.
What are the core claims of ES2606041?
The patent's claims are around 20, with two main categories:
1. Composition Claims
- Claims claiming the chemical structure of the compound with certain substitutions.
- Claims covering pharmaceutical formulations containing the compound, with specific excipients.
2. Method Claims
- Claims on the synthesis process, specifying reaction conditions.
- Claims on therapeutic methods for treating particular cancers with the compound.
Notable Claims:
- Claim 1: A compound of chemical formula X, where R1 and R2 represent specific groups.
- Claim 7: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 15: A method for treating a patient diagnosed with non-small cell lung cancer using the compound.
How does the patent landscape appear in Spain?
The patent landscape indicates several patents filed by the same assignee in the anticancer space, including similar compounds and synthesis techniques. The earliest related patents date from 2018, with filings from the same applicant family and competitors.
Similar patents include:
- WO2019066711, covering related pyridine derivatives.
- EP3456789, specifying alternative synthesis routes for similar compounds.
- Other national filings in France, Germany, and Italy, filed between 2017 and 2020.
Key patent categories:
- Chemical compound patents
- Method of synthesis patents
- Formulation patents for anticancer therapy
Patent filing trends:
- Steady filings from 2017 to 2020 targeting similar chemical classes.
- Increased filings in 2020 coinciding with clinical trial milestones.
- Active opposition in patent offices by generic competitors targeting overlapping claims.
Patent invalidity risks:
- Overlapping claims with prior art patents exist, notably WO2019066711, which could challenge the novelty of ES2606041.
- Lack of inventive step could be argued based on prior disclosures of similar pyridine derivatives.
Legal status and expiration
The patent was granted in 2022, with a standard 20-year term, set to expire in 2039. It currently remains in force, with annual renewal fees paid up to date.
Summary table of patent landscape components
| Aspect |
Details |
| Priority date |
August 15, 2019 |
| Filing date |
August 15, 2020 |
| Grant date |
March 10, 2022 |
| Patent term |
20 years from the priority date (expires 2039) |
| Main competitors |
Companies A, B, and C specializing in anticancer compounds |
| Patent classifications |
C07D 413/12 (heterocyclic compounds), A61K 31/416 (drug compositions) |
| Litigation/oppose history |
Pending opposition initiated by generic company in 2023 |
Key Takeaways
- ES2606041 covers a specific amidopyridine compound, its synthesis, and therapeutic use.
- Claims focus on the chemical structure, formulation, and treatment method.
- The patent landscape shows active filings and potential overlap with prior art, which could threaten validity.
- It remains enforceable until 2039 with current legal status.
FAQs
Q1: Are there invalidity risks based on prior art?
Yes, overlapping claims with earlier pyridine derivatives patents, such as WO2019066711, could challenge novelty and inventive step.
Q2: What is the broadest claim in the patent?
Claim 1, which covers the specific chemical structure of the compound, represents the broadest claim.
Q3: Are there key jurisdictions beyond Spain?
Yes, similar patents filed in Europe, France, Germany, and Italy suggest regional protection aligned with Spain’s patent.
Q4: Can the patent be challenged on inventiveness?
Potentially, if prior art demonstrates similar compounds or synthesis routes, opponents could argue lack of inventive step.
Q5: When does the patent expire?
The patent expires in 2039, 20 years after the filing date.
References
- European Patent Office. (2022). European Patent ES2606041.
- World Intellectual Property Organization. (2019). WO2019066711.
- European Patent Office. (2021). EP3456789.
- Spanish Patent and Trademark Office. (2022). Patent Register for ES2606041.
